67 Kazia Theraputics Limited Annual Report 2022 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports Note 24. Key management personnel disclosures Compensation The aggregate compensation made to directors and other members of key management personnel of the consolidated entity is set out below: Consolidated 2022 2021 $ $ Short-term employee benefits 2,589,088 1,574,520 Post-employment benefits 115,950 112,290 Share-based payments 1,559,930 616,598 4,264,968 2,303,408 Please refer to Note 28 for other transactions with key management personnel and their related parties. Note 25. Remuneration of auditors During the financial year the following fees were paid or payable for services provided by Grant Thornton Audit Pty Ltd, the auditor of the company: Consolidated 2022 2021 $ $ Audit services - Grant Thornton Audit Pty Ltd Audit or review of the financial statements 154,935 151,400 Other services - Grant Thornton Audit Pty Ltd Comfort letter ATM 25,719 - 180,654 151,400 Comfort letter ATM refers to the fee in relation to Comfort Letter provided to Oppenheimer for ATM facility. Note 26. Contingent liabilities Other than the contingent consideration set out in note 16, the consolidated entity does not have any other contingent liabilities. Note 27. Commitments Lease commitments comprise contracted amounts for leases of premises. The agreement has a duration less than 12 months from financial year end. Note 28. Related party transactions Parent entity Kazia Therapeutics Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 30. Key management personnel Disclosures relating to key management personnel are set out in note 24 and the remuneration report included in the directors’ report. Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3